| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
N/A |
| Shares
Out: |
61,150,000 |
| Market
Cap: |
6.68(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$113.49 - $145.93 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for patients with serious diseases with limited or no options. Co.'s primary marketed products are: Xyrem® (sodium oxybate) oral solution, for the treatment of both cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Xywav™ (calcium, magnesium, potassium, and sodium oxybates) oral solution, for the treatment of cataplexy or EDS in narcolepsy patients seven years of age and older; and Sunosi® (solriamfetol), to improve wakefulness in adult patients with EDS associated with narcolepsy or obstructive sleep apnea.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
12,000 |
12,000 |
12,000 |
12,000 |
| Total Buy Value |
$1,435,800 |
$1,435,800 |
$1,435,800 |
$1,435,800 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
8,704 |
9,538 |
26,327 |
202,744 |
| Total Sell Value |
$986,699 |
$1,086,171 |
$3,399,099 |
$29,455,215 |
| Total People Sold |
2 |
4 |
12 |
19 |
| Total Sell Transactions |
3 |
5 |
21 |
74 |
| End Date |
2024-02-29 |
2023-11-28 |
2023-05-30 |
2022-05-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Tovey Christopher J. |
EVP COO & Managing Dir EUR/INT |
• – – |
2021-05-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
25 |
|
- |
|
| Tovey Christopher J. |
EVP COO & Managing Dir EUR/INT |
• – – |
2021-05-05 |
4 |
A |
$0.00 |
$0 |
D/D |
9,091 |
9,116 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2021-05-05 |
4 |
AS |
$170.00 |
$85,000 |
D/D |
(500) |
321,341 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2021-05-03 |
4 |
AS |
$164.24 |
$246,360 |
D/D |
(1,500) |
321,841 |
|
- |
|
| Gala Renee D |
EVP & CFO |
• – – |
2021-04-05 |
4 |
D |
$164.71 |
$249,536 |
D/D |
(1,515) |
25,347 |
|
- |
|
| Carr Patricia |
VP, Finance & PAO |
• – – |
2021-03-09 |
4 |
S |
$161.50 |
$155,202 |
D/D |
(961) |
6,045 |
|
- |
|
| Larkin Finbar |
SVP, Technical Operations |
• – – |
2021-03-08 |
4 |
S |
$161.60 |
$243,859 |
D/D |
(1,509) |
16,519 |
|
- |
|
| Carr Patricia |
VP, Finance & PAO |
• – – |
2021-03-08 |
4 |
S |
$161.61 |
$175,988 |
D/D |
(1,089) |
7,006 |
|
- |
|
| Pearce Samantha |
SVP, Head of Europe & Intl |
• – – |
2021-03-05 |
4 |
D |
$164.75 |
$230,980 |
D/D |
(1,402) |
11,958 |
|
- |
|
| Iannone Robert |
EVP R&D, Chief Medical Officer |
• – – |
2021-03-05 |
4 |
D |
$164.75 |
$122,080 |
D/D |
(741) |
30,145 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2021-03-05 |
4 |
D |
$164.75 |
$3,544,761 |
D/D |
(21,516) |
324,841 |
|
- |
|
| Patil Neena M |
SVP, General Counsel |
• – – |
2021-03-05 |
4 |
D |
$164.75 |
$113,842 |
D/D |
(691) |
26,147 |
|
- |
|
| Swisher Daniel N Jr |
President and COO |
• – – |
2021-03-05 |
4 |
D |
$164.75 |
$612,541 |
D/D |
(3,718) |
49,961 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2021-03-01 |
4 |
AS |
$170.00 |
$1,632,000 |
D/D |
(9,600) |
346,357 |
|
- |
|
| Smith Mark Douglas |
Director |
– • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,590 |
2,590 |
|
- |
|
| Patil Neena M |
Chief Legal Officer (CLO) and |
• – – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
7,270 |
26,838 |
|
- |
|
| Cozadd Bruce C |
Chairman & CEO |
• • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
37,925 |
355,957 |
|
- |
|
| Carr Patricia |
VP, Finance & PAO |
• – – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
1,895 |
8,095 |
|
- |
|
| Gala Renee D |
EVP & CFO |
• – – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
10,115 |
26,862 |
|
- |
|
| Sablich Kim |
EVP & GM, North America |
• – – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
8,535 |
25,335 |
|
- |
|
| Cook Jennifer E. |
Director |
– • – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
2,590 |
2,590 |
|
- |
|
| Pearce Samantha |
SVP, Head of Europe & Intl |
• – – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,160 |
13,360 |
|
- |
|
| Swisher Daniel N Jr |
President and COO |
• – – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
11,695 |
53,679 |
|
- |
|
| Larkin Finbar |
SVP, Technical Operations |
• – – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
3,950 |
18,028 |
|
- |
|
| Iannone Robert |
EVP, Research & Development |
• – – |
2021-02-25 |
4 |
A |
$0.00 |
$0 |
D/D |
8,535 |
30,886 |
|
- |
|
881 Records found
|
|
Page 11 of 36 |
|
|
0.37 (0.34%) 
